The latest Business updates from the science industry


by Gwyneth Astles


Strategic appointment to support biopharma expansion


Coriolis Pharma has appointed industry heavyweight Peter Sölkner to its Board of Directors, a move that signals the company’s intent to accelerate its global growth strategy and deepen its role as a key partner in biopharma innovation.


Sölkner, who brings over three decades of experience in pharmaceutical services, is best known for his leadership at Vetter Pharma, where he helped scale the business fi vefold. Now, as a non-executive director at Coriolis, he’ll lend his expertise to one of the sector’s most respected formulation specialists.


“I’m excited to support Coriolis as it grows its impact in developing life-changing therapies,” said Sölkner. “The team’s scientifi c excellence and forward-looking approach make it a standout partner in the biotech fi eld.”


Peter Sölkner.


Known for its cutting-edge work in biologics, cell and gene therapies, and vaccine development, Coriolis Pharma has earned a reputation as a premier CRDO. The appointment of Sölkner strengthens its Board at a pivotal time, as the company sharpens its focus on integrated services from preclinical through to commercialisation.


Dr Michael Wiggenhorn, Coriolis Founder and Board Member, welcomed the appointment: “Peter’s track record in scaling businesses and his understanding of the CDMO landscape bring exactly the kind of insight we value.”


CEO Silvia Steyrer-Gruber added: “We see our role as a bridge between early discovery and fi nal product. Peter’s experience will help us better support both pharma innovators and manufacturing partners.”


Sölkner’s previous roles at Sartorius and Vetter, combined with his


international leadership experience and technical background, make him a strategic asset as Coriolis strengthens its collaborations across the pharmaceutical value chain.


More information online: ilmt.co/PL/bjO5 64411pr@reply-direct.com


40-year milestone for Swiss pharma group


Pharmaceutical group IBSA (Institut Biochimique SA) is marking 40 years under the leadership of President and CEO Arturo Licenziati in 2025, alongside the 80th anniversary of the company’s founding.


Licenziati assumed control of the Lugano-based company in 1985, at a time when IBSA was a small enterprise with 40 employees and annual revenues of 5 million Swiss francs. Over the following decades, the company has grown into an international pharmaceutical group with more than 2,300 staff, 20 subsidiaries across Europe, China, and the US, and distribution networks spanning over 90 countries.


Under Licenziati’s direction, IBSA focused on identifying overlooked therapeutic areas and developing reformulated drugs designed for improved delivery and patient experience. This


approach, summed up in the company’s long-standing philosophy of providing ‘drugs in the best form’, has supported consistent growth and product diversifi cation.


“We’ve always focused on unmet needs and simple but meaningful innovations,” said Licenziati. “That has allowed us to grow steadily while staying close to our core values.”


To mark the anniversary, all IBSA employees will receive an additional day of leave on 19 August, commemorating the date Licenziati fi rst joined the company in 1985.


IBSA’s expansion over the past 40 years reflects its strategic pivot from a small pharmaceutical manufacturer in the Swiss canton of Ticino to a multinational player in the life sciences sector.


More information online: ilmt.co/PL/89wp 64414pr@reply-direct.com


Kenya expansion to drive diagnostics growth across East Africa


Sysmex Corporation has established a new subsidiary in Nairobi, Kenya, to support growing demand for healthcare diagnostics in East Africa and strengthen its presence on the continent. The move is part of the company’s strategy to accelerate business in emerging markets by improving local infrastructure and customer support.


The newly formed Sysmex East Africa Ltd will serve as a hub for nine countries in the region. Working alongside Sysmex’s existing base in South Africa, the subsidiary will focus on expanding access to diagnostics solutions through both direct


sales and collaboration with regional distributors.


East Africa is seen as a key growth area within the continent, with rising healthcare spending and an increasing need for accessible medical services. Sysmex’s expansion aims to address these needs by offering products tailored to local requirements, while delivering consistent global standards in customer care, training, and supply chain reliability.


The company has been steadily increasing its footprint across Africa since launching its South African operations in 2006, followed by new bases in Burkina Faso, Ghana, and Egypt. The


addition of a Kenyan office marks its fifth African subsidiary and reflects growing demand for diagnostics solutions to support healthcare systems in developing regions.


Sysmex says the move also aligns with broader sustainable development goals, contributing to improved health outcomes and infrastructure in underserved markets.


More information online: ilmt.co/PL/RGmN 64418pr@reply-direct.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56